Pfizer and Allergan wend toward a $150B merger, reports say

Pfizer ($PFE) and Allergan ($AGN) are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $150 billion, at a price of $370 to $380 per share, according to media reports, though analysts have estimated a per-share price of up to $400. Bloomberg says an announcement could come as soon as Monday, though CNBC's sources peg the due date as the Monday after Thanksgiving. The two sides are "in the final stages" of negotiations, CNBC reports. More from FiercePharma

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.